Objective : The purpose of the study is to determine the effectiveness and safety of nicardipine infusion for controlling blood pressure in patients with subarachnoid hemorrhage (SAH).
INTRODUCTION
Non-traumatic subarachnoid hemorrhage (SAH) occupies approximately 5-6% of all strokes. 23) The incidence of SAH is around six cases per 100,000 patient years, and the most common cause of SAH is a rupture of a saccular cerebral aneurysm. 21) Aneurysmal rebleeding is a serious and disastrous complication of SAH, and it comes with high mortality and morbidity.
The incidence of aneurysmal rebleeding is considerably high within hours after the initial SAH (21.5% within 72 hours). 8) Unfortunately, re-bleeding cannot be absolutely controlled even in authoritative neurosurgical centers that performs early aneurysm repair, such as aneurysm neck clipping or endovascular coiling. Several investigators have reported that rebleeding occurs more often in patients with advanced age, larger aneurysms, poor clinical condition, and increased systolic arterial blood pressure (SBP) on admission. 5) 12) The incidence of rebleeding was significantly higher in patients with extremely high SBP group (> 200 mmHg) (55.6%) than in the lower SBP groups (< 150 mmHg, 150-200 mmHg). 7) Therefore, it is important to control the blood pressure.
Nicardipine(Perdipine

Ⓡ
) is a dihydropyridine type calcium channel blocker and has strong antihypertensive activity and a particular cerebrovascular profile. 2) Nicardipine has been used to control blood pressure in severe hypertension after ischemic stroke, traumatic brain injury, intracerebral hemorrhage (ICH), and to improve vasospasm after SAH.
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In a recent study, Qureshi et al. 19) reported the feasibility and safety of nicardipine use in treatment of acute hypertension with ICH, and Varelas et al. 22) demonstrated nicardipine infusion for controlling elevated blood pressure after SAH. However, the study showing controlling acute hypertension after SAH is limited. The purpose of this study is to evaluate the effectiveness and safety of nicardipine infusion for controlling blood pressure in patients with SAH, and compare the effectiveness for each Fisher grade, for different dose of continuous nicardipine infusion, and for various ranges of systolic blood pressure.
MATERIALS AND METHODS
We prospectively evaluated 112 patients with rup- 
RESULTS
Fifty two patients, who fulfilled the condition, were injected with nicardipine. Their demographics and clinical characteristics are presented in table (Table 1) .
In forty patients who were not responsive to bolus injection, the mean blood pressure in three periods were compared. From pre-injection period (145.6/80.3 mmHg), 11.4/9.0 mmHg was reduced after bolus injection, whereas 24.7/17.3 mmHg was reduced after continuous injection. The effect of nicardipine in controlling blood pressure was statistically significant (p < 0.001) ( Table 2 ). mmHg. There was significant decrease in blood pressure in both groups (SBP in both groups p < 0.001, DBP in both groups p = 0.01) ( Table 5) . There were few complication during nicardipine infusion (Table 1) . No patient developed rebleeding and renal dysfunction during the period. In one case, which infused 2.5 mg/hr of nicardipine, the SBP of the patient dropped to 94 mmHg and DBP to 33 mmHg; thus, nicardipine had to be pre-terminated.
Cardiogenic problems occurred in four patients.
Tachycardia with heart rates more than 120 beats per minute appeared in two patients, and arrhythmia was combined in two patients, in which one of them showed ventricular premature contraction, and another showed atrial fibrillation.
DISCUSSION
Nicardipine, a dihydropyridine calcium channel antagonist, is a vasoselective agent with minimal cardiac inotropic effects. 23) This is the ideal agent for shortterm management of hypertension because of short half life and relatively rapid onset/offset of action in lowering blood pressure with minimal adverse events. 6) Hypotension, arrhythmia and tachycardia were some adverse effects observed in this study but there was no severe events.
There has been studies comparing the effectiveness of nicardipine and sodium nitroprusside or nicardipine and labetalol and evaluating effectiveness of nicardipine in traumatic brain injury, SAH, ICH, arteriovenous malformation, and hypoxic brain injury.
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Recently, Varelas et al. 22) reported effectiveness and safety of nicardipine infusion in reducing SBP and DBP to pre-specified goal. Nicardipine achieved SBP control in 59.9% of hourly infusion measurements.
Intravenous nicardipine has already been included in the published guidelines for blood pressure control in ischemic stroke, ICH. 1)4) The recently published guidelines for SAH also include nicardipine, however, without available data for such a use.
3)
In this study, continuous injection was the most effective method in decreasing blood pressure compared with bolus injection. In some cases, which we manipulated the injection method from bolus to continuous, the influence of bolus injection cannot be ignored even though nicardipine is a short acting agent.
This study also showed no significant difference in effectiveness of nicardipine to control blood pressure The risk of rebleeding decrease as the blood pressure decreases, but lowering the blood pressure is not everything. One study reported a increase in rebleeding risk with blood pressure over 160 mmHg compared with 140 mmHg, and rebleeding incidence decreased when anti-hypertensive treatment was used. 17) In contrast, risk of cerebral infarction rate increases with low blood pressure. 24) The optimal blood pressure after SAH would dependent on multiple factors.
In addition, appropriate management of blood pressure is necessary because most rebleeding occurs due to the change of blood pressure rather than absolute blood pressure level itself. 15 
